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Abstract
Magnesium status and vitamin B6 intake have been linked to mental health and/
or quality of life (QoL). In an 8‐week Phase IV randomised controlled study in
individuals with low magnesemia and severe/extremely severe stress but who
were otherwise healthy, greater stress reduction was achieved with magnesium
combined with vitamin B6 than with magnesium alone. We present a previously
unreported secondary analysis of the effect of magnesium, with and without
vitamin B6, on depression, anxiety, and QoL. Adults with Depression Anxiety
Stress Scales (DASS‐42) stress subscale score >18 were randomised 1:1 to
magnesium + vitamin B6 combination (Magne B6®; daily dose 300 and 30 mg,
respectively) or magnesium alone (Magnespasmyl®; daily dose 300 mg). Out-
comes included changes from baseline in DASS‐42 depression and anxiety scores,
and QoL (Short Form‐36 Health Survey). DASS‐42 anxiety and depression scores
significantly improved from baseline to week 8 with both treatments, particularly
during the first 4 weeks. Improvement in QoL continued over 8 weeks. Partici-
pants' perceived capacity for physical activity in daily life showed greater
improvement with magnesium + vitamin B6 than magnesium alone (Week 4). In
conclusion, magnesium supplementation, with or without vitamin B6, could pro-
vide a meaningful clinical benefit in daily life for individuals with stress and low
magnesemia.
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1 | INTRODUCTION
Advances in understanding the neurobiology of stress have demon-
strated an interplay between disturbances in biochemical processes
and physical and mental symptoms (McEwen, 1998). The protective
biological responses that occur in response to stressors (allostasis)
usually involve activation of neural, neuroendocrine and
neuroendocrine‐immune mechanisms (McEwen, 2005). However,
over long periods of time, allostatic overload can occur, resulting in
mood disorders, chronic illness and reduced quality of life (QoL;
Juster et al., 2010; McEwen, 2005; McEwen & Wingfield, 2003).
Furthermore, components of the allostatic system have been asso-
ciated with depression‐ and anxiety‐like behaviours (McEwen, 2015).
Since the cumulative effect of daily stress has been linked to symp-
toms of anxiety and depression up to 10 years later (Charles
et al., 2013), it follows that chronic stress, anxiety and depression
could be viewed as a continuum of the same condition.
Magnesium status has been shown to be linked to anxiety,
depression and mood changes (Boyle et al., 2017; Derom et al., 2013;
Forsyth et al., 2011; Jung et al., 2010). During periods of stress,
catecholamines and corticosteroids are released; prolonged release
of these stress‐associated hormones then cause a progressive loss of
magnesium from body stores (Galland, 1991‐1992). Since low mag-
nesium status results in further release of catecholamines and cor-
ticosteroids a positive feedback loop that exacerbates magnesium
depletion is created (Cuciureanu & Vink, 2011).
As magnesium is an enzymatic cofactor in over 600 biochemical
reactions (de Baaij et al., 2015), magnesium deficiency could affect
allostatic regulation in multiple ways. Magnesium influences activity
of the hypothalamic‐pituitary‐adrenal axis, which instigates various
responses to cope with stress demands (Murck, 2002). Magnesium
also reduces central adrenocorticotrophic hormone (Murck, 2002)
and peripheral (cortisol) endocrine responses (Held et al., 2002),
thereby decreasing anxiety. Additionally, magnesium may help
reduce presynaptic glutamate release (Papadopol & Nechifor, 2011)
and glutamatergic activity that has been implicated in fear, anxiety
and panic responses (Boyle et al., 2017; Clerc et al., 2013).
Magnesium levels have also been linked with general health and
QoL; a retrospective study (n = 81) showed that the higher magne-
sium levels were associated with improved QoL scores in all 10
categories of the Short Form‐36 Health Survey (SF‐36) measuring
QoL and health (Viebahn et al., 2016). Magnesium supplementation is
therefore of interest not only as a potential aid to coping with stress,
but also as a treatment for anxiety and depression (Botturi
et al., 2020; Boyle et al., 2017; Kirkland et al., 2018). However, to
date, no evidence has shown that magnesium supplementation can
result in improved QoL.
Pyridoxine (vitamin B6) plays an important role in numerous
physiological processes. It acts as a cofactor in over 100 enzymatic
reactions, including in the synthesis of neurotransmitters such as
gamma‐aminobutyric acid, serotonin and dopamine (Sato, 2018). In
addition to modulating neurobiological mechanisms associated with
mood disorders such as depression and anxiety (McCarty, 2000),
vitamin B6 may have other stress‐reducing properties, including
hypotensive effects and may reduce the physiological consequences
of corticosteroid release (McCarty, 2000).
Inadequate intake of vitamin B6 has recently been linked to an
increased risk of anxiety and depression in a cross‐sectional study of
over 3,000 individuals (Kafeshani et al., 2019). Furthermore, vitamin
B6 supplementation has demonstrated beneficial effects on
emotional symptoms, such as reducing irritability, depression and
tiredness (Doll et al., 1989). Vitamin B6 may also modulate magne-
sium levels, with some evidence showing increased circulating and
tissue magnesium concentrations following high‐dose vitamin B6
supplementation (Abraham et al., 1981; Iezhitsa et al., 2011;
Majumdar & Boylan, 1989). As both vitamin B6 and magnesium
modulate neurobiological mechanisms, it has been hypothesized that
they may have a synergistic effect (De Souza et al., 2000; Iezhitsa
et al., 2011; Pouteau et al., 2018).
In the primary analysis of a Phase IV randomised controlled
study (Pouteau et al., 2018), vitamin B6 augmented the beneficial
effect of magnesium supplementation on stress relief, in healthy
adults with low magnesemia and severe or extremely severe sub-
jective stress at baseline. Over the 8‐weeks study period, a marked
reduction in stress levels from baseline was observed with magne-
sium supplementation. In addition, magnesium supplementation
combined with vitamin B6 resulted in greater improvements than
magnesium alone. Based on these findings and other evidence from
the literature, we conducted a secondary, post‐hoc analysis of the
study by Pouteau and colleagues (2018) to explore whether mag-
nesium supplementation improves anxiety and depression (Depres-
sion Anxiety Stress Scales [DASS‐42]) and QoL (SF‐36) in this cohort
of stressed but otherwise healthy subjects. Furthermore, we explored
whether addition of vitamin B6 to magnesium supplementation en-
hances any observed effects on mental health and QoL.
2 | METHODS
2.1 | Trial design
This 8‐weeks Phase IV, randomised, investigator‐blinded, parallel‐
group trial (EudraCT Number: 2015‐003749‐24) compared the
combination of magnesium and vitamin B6 with magnesium alone.
Participants were recruited at four clinical trial centres in France.
Eligible participants were adults aged 18–50 years with moderate to
extremely severe stress at screening, defined as having a DASS‐42
stress subscale score of >18 and with suboptimal serum magne-
sium levels (range 0.66–0.84 mmol/L; Pouteau et al., 2018). Details of
participant demographics and characteristics at baseline have pre-
viously been reported (Pouteau et al., 2018; Noah et al., 2020).
Briefly, mean (standard deviation [SD]) age was 31.6 (8.5) years, 74%
were female and mean (SD) DASS‐42 stress score was 27.7 (7.1)
(severe stress: 26–33). Mean (SD) serum level of magnesium and
vitamin B6 was 0.80 (0.04) mmol/L and 48.56 (52.27) nmol/L,
respectively (levels after 4 and 8 weeks are described elsewhere
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[Noah et al., 2020]). Demographic and clinical characteristics were
similar between treatment groups.
Participants were randomised 1:1 to treatment with either the
magnesium + vitamin B6 combination (Magne B6®; 300 mg as
magnesium lactate dihydrate and 30 mg vitamin B6 daily) or mag-
nesium alone (Magnespasmyl®; 300 mg daily as magnesium lactate
dihydrate). Participants could follow their regular diet during the 8‐
weeks study period, and were asked to maintain monotherapy
(magnesium + vitamin B6 or magnesium alone) for the study duration
and not to take medications known to affect magnesium status (e.g.,
magnesium‐containing salts, levodopa or tetracyclines, phosphate or
calcium salts, nonsteroidal anti‐inflammatory drugs) or to consume
vitamin/mineral supplements or magnesium‐rich foods (e.g., dark
chocolate, <50 g per day) or drinks (≤2 glasses per day; Noah
et al., 2020). Investigators remained blinded with regard to the
assigned study treatment until the database lock (Pouteau
et al., 2018). The primary endpoint (subjective stress rating) was
reported in Pouteau et al. (2018).
This article presents key secondary endpoints focused on anxiety
and depression, based on a post‐hoc analysis. For full details of in-
clusion and exclusion criteria, treatments and primary trial endpoints,
see Pouteau et al. (2018). Ethical approval for the trial and all ana-
lyses planned within the protocol was obtained from the Ethics
Committee of Clermont‐Ferrand University Hospital, France (Comité
de Protection des Personnes Sud Est 6; reference number: AU 1239,
date of approval 01 March 2016), and all patients provided written
informed consent.
2.2 | Assessments and endpoints
The objective of these secondary and post‐hoc analyses was to
explore the impact of magnesium (and vitamin B6) supplementation
on mental and physical health in the participants by analysing DASS‐
42 scores and SF‐36 scores at baseline, Week 4 and Week 8.
The self‐reported DASS‐42 is a 42‐item questionnaire that in-
cludes three subscales designed to measure the negative emotional
states of depression, anxiety and stress and has been validated for
clinical conditions (Brown et al., 1997; Crawford & Henry, 2003). In
this study, DASS‐42 scores for anxiety and depression, as well as a
total score were assessed at baseline, Week 4 and Week 8, and the
change from baseline to Week 4 or Week 8 was calculated for each
of the endpoints.
The SF‐36, validated for measuring QoL in a general practice
population, examined the inter‐relationship between mental and
physical health (Brazier et al., 1992). The 36‐item questionnaire
comprises eight domains: physical role functioning (a measure of
perceived capacity to participate in ordinary activities), bodily pain,
role limitations due to physical health problems, role limitations due
to personal or emotional problems, emotional well‐being, social
functioning, energy/fatigue, and general health perceptions. Scores
for each domain were derived following the guidance of Ware and
Sherbourne (1992). Scores range from 0 to 100, where higher scores
indicate better QoL, and scores <50 indicate poor QoL. The following
endpoints were assessed at baseline, Week 4 and Week 8: separate
SF‐36 scores for all eight domains, an overall SF‐36 physical score
summary, and a SF‐36 mental score summary. The change from
baseline to Week 4 or Week 8 was calculated for each of the end-
points. Reference data from a historical cross‐sectional survey of the
French metropolitan population (Leplège et al., 2001) were retrieved
to provide context for the current study population.
2.3 | Statistical analyses
Analyses were performed on the intent‐to‐treat (ITT) population (all
randomised participants with at least one consumption of study
product), comprising 264 patients (132 patients in each treatment
group; Pouteau et al., 2018).
Data collected from the DASS‐42 and SF‐36 assessments were
analysed using the same statistical approach. For the two treatment
groups separately and after pooling (Overall group), descriptive sta-
tistics including the mean and SD were used to initially summarize
scores at each visit (baseline, Week 4, and Week 8) and the change in
score from baseline to Week 4 and Week 8. Subsequently, a Model
Mixed for Repeated Measures (MMRM) including sex and visit as
categorical fixed effects, DASS‐42 or SF‐36 at baseline as a continuous
fixed effect, and subject as a random effect, was used to estimate dif-
ferences over time within each treatment group and the overall group.
Adjusted means, standard errors (SE), 95% confidence intervals (CI)
and p‐values were calculated. Differences between the two treatment
groups in terms of change from baseline to Week 4 and Week 8 for
DASS‐42 and SF‐36were also assessed using the aboveMMRMmodel
but modified to include treatment group as a further categorical fixed
effect and two interaction terms: DASS‐42 or SF‐36 at baseline x
treatment group, and visit x treatment group. Data are reported as
adjusted means, SE, 95% CI and p‐values. An alpha level of 5% with a
two‐sided test was used for all comparisons. As these post‐hoc ana-
lyses were intended to identify trends and be hypothesis generating,
correction for multiple testing was not performed (to minimize type II
errors). Correcting for multiple testing is a very conservative approach
that reduces the likelihood of making a type I error (false positive);
however, it is of no less importance that doing so simultaneously in-
creases the likelihood of type II errors (false negatives), which is
especially relevant for exploratory, post‐hoc analyses such as these.
Analyses were performed using SAS version 9.4 software.
3 | RESULTS
3.1 | Anxiety and depression
At the baseline time point, DASS‐42 anxiety and depression scores
were similar for the two treatment groups, magnesium + vitamin B6
and magnesium alone (Table 1). Adjusted mean DASS‐42 anxiety and
depression subscale scores at each visit are in Figure 1.
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Both treatment groups showed improved anxiety scores over the
course of the 8‐weeks study, with mean anxiety scores reducing from
a severe level to a near normal level (Figure 1). Greatest improve-
ment in mean anxiety score occurred in the first 4 weeks of treat-
ment; the overall group mean score decreased from baseline by
−5.86 (95% CI −6.67; −5.04). However, no significant difference was
observed between the magnesium + vitamin B6 and magnesium
alone groups at either Week 4 or 8 (Table 2).
Across the overall population, participants in both treatment
groups improvedDASS‐42 depression scores over the course of the 8‐
weeks study (Figure 1b), such that, depression scores reduced from
moderate to normal (≤9). In both groups, most of the improvement in
the depression score occurred in the first 4 weeks of treatment (mean
decrease from baseline −5.54 [95% CI −6.47; −4.61 overall]). No sig-
nificant difference was observed between magnesium + vitamin B6
and magnesium alone groups at either Week 4 or 8 (Table 2).
3.2 | Quality of life
QoL changes from baseline, by visit and by treatment group, assessed
using the SF‐36 questionnaire, are shown in Table 3. Table S1 pre-
sents the SF‐36 scores by visit and by treatment group. The adjusted
mean physical QoL summary score at baseline was similar for both
treatment groups (52.6 for the magnesium + vitamin B6 group; 53.1
for magnesium alone) (Table 3). The adjusted mean mental summary
score also did not differ between the treatment groups at the initial
visit (30.4 for the magnesium + vitamin B6 group; 29.6 for magne-
sium alone). These baseline mental summary scores were low
compared to the initial physical summary scores, which is reflective
of the stressed status of this otherwise healthy study population.
3.3 | SF‐36 domains
Figure 2 represents the SF‐36 data as a radar plot. All mental domain
scores (role limitations due to personal or emotional problems,
emotional well‐being, social functioning, energy/fatigue) were very
low at baseline with regard to the reference population (historical
cross‐sectional population from the French metropolitan area [Lep-
lège et al., 2001]). Across the 8 weeks of magnesium supplementa-
tion, ongoing improvements were observed in all SF‐36 domains,
reaching levels close to those of the reference population. Improve-
ments were most pronounced in the mental domain, but were also
observed in the physical domain. For example, a relevant improve-
ment was observed for the emotional role functioning domain where
participants had a baseline score of 34.3 (95% CI 30.6; 38.0) and
ended up with a score of 69.9 (95% CI 66.2; 73.6) after the 8‐weeks
study period (Table 3).
Although improvements from baseline were observed in the
SF‐36 physical role functioning domain in both treatment groups, a
significantly greater improvement at the 4‐week time point
occurred in participants who received magnesium + vitamin B6
compared with those who received magnesium alone (change from
baseline to Week 4: 14.6 ± 2.5 vs. 4.6 ± 2.7, respectively;
p = 0.025; Table 3). There was continued improvement with both
treatments at Week 8, with the mean change from baseline
increasing by 7.8 points from Week 4 to Week 8 for the magne-
sium + vitamin B6 group and by 9.1 points for the magnesium
alone group. The difference between treatments in change from
baseline to Week 8 was not statistically significant (p = 0.059;
Table 3). The general health domain score improved from baseline
in both treatment groups, with participants receiving magnesium
alone showing a significantly greater improvement at Week 4 than
T A B L E 1 DASS‐42 anxiety and depression scores at baseline time point in two magnesium supplemented groups and in the overall ITT
population
Parameter Magnesium + vitamin B6 (N = 132) Magnesium (N = 132) Total (N = 264)
DASS‐42 anxiety n (%) n (%) n (%)
Normal (scale 0–7) 25 (18.9) 26 (19.7) 51 (19.3)
Mild (8–9) 7 (5.3) 10 (7.6) 17 (6.4)
Moderate (10–14) 31 (23.5) 27 (20.5) 58 (22.0)
Severe (15–19) 25 (18.9) 24 (18.2) 49 (18.6)
Extremely severe (20–42) 44 (33.3) 45 (34.1) 89 (33.7)
DASS‐42 depression n (%) n (%) n (%)
Normal (scale 0–9) 47 (35.6) 43 (32.6) 90 (34.1)
Mild (10–13) 18 (13.6) 20 (15.2) 38 (14.4)
Moderate (14–20) 33 (25.0) 33 (25.0) 66 (25.0)
Severe (21–27) 16 (12.1) 23 (17.4) 39 (14.8)
Extremely severe (28–42) 18 (13.6) 13 (9.8) 31 (11.7)
Note: No significant differences (p < 0.05) were identified between the magnesium + vitamin B6 group and magnesium group (Chi square test). DASS‐42
at baseline was included in the analysis models to account for any disparities observed at baseline.
Abbreviations: DASS‐42, Depression Anxiety Stress Scales; ITT, intent‐to‐treat.
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those receiving magnesium + vitamin B6 (change from baseline to
Week 4: 8.1 ± 1.1 vs. 4.6 ± 1.0, respectively; p = 0.046; Table 3).
4 | DISCUSSION
This secondary analysis shows that magnesium (with or without
vitamin B6) improved mood and anxiety, and improved associated
QoL, in stressed but otherwise healthy adults. Magnesium (with or
without vitamin B6) significantly improved baseline depression and
anxiety scores of the DASS‐42 scale to normal or near normal levels
by Week 8, with greatest change observed during the first 4 weeks.
Improvements in SF‐36 QoL after 4 to 8 weeks were observed with
both treatments, for all mental domains and most physical domains.
Of note, participants' perception of being physically limited in their
daily activities (physical role functioning) improved significantly
more at Week 4 (similar trend at Week 8) with magnesium sup-
plementation when combined with vitamin B6 than without. These
clinical data support magnesium as a treatment for improving
stress‐related mental health in individuals with suboptimal magne-
semia and the further evaluation of a potential additional benefit
with vitamin B6.
F I G U R E 1 DASS‐42 scores (adjusted
means) for (a) anxiety and (b) depression by
treatment and visit. *Statistically significant
(p < 0.05) differences between baseline and a
given post‐baseline visit using MMRM.
Horizontal dashed lines represent the upper
limit of each DASS‐42 category. Abbreviations:
CI, confidence interval; DASS‐42, Depression
Anxiety Stress Scales; MMRM, Model Mixed
for Repeated Measures
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4.1 | Effect of magnesium on mental health and QoL
Our findings support earlier findings, which demonstrate the poten-
tial of magnesium in the treatment of anxiety and depression (Botturi
et al., 2020; Derom et al., 2013; Jung et al., 2010) as well as stress
(Pouteau et al., 2018). They are also consistent with the findings of
Forsyth et al. (2011) who reported that worse self‐reported
depression was associated with lower magnesium intake (as a per-
centage of estimated average requirements) in a cohort of adults
prior to treatment for depression and anxiety. Furthermore, our
findings are consistent with previous reports of beneficial effects of
magnesium supplementation on depression (Eby & Eby, 2006; Raji-
zadeh et al., 2017; Ryszewska‐Pokraśniewicz et al., 2018; Tarleton
et al., 2017), anxiety (Boyle et al., 2017) and mood (Derom
et al., 2013; Szewczyk et al., 2008). We saw marked improvement in
both mental and physical aspects of QoL. Despite the importance of
magnesium in human physiology, data on the effect of magnesium on
QoL are scarce. To our knowledge, there has been only one previous
study showing that magnesium prophylaxis for migraine improved
QoL in a paediatric population (Kovacevic et al., 2017). In our study,
physical domain SF‐36 scores at baseline were shown to be higher
than reference data from a historical survey of a cross‐section of the
French metropolitan population (Leplège et al., 2001; Figure 2). This
may be due to the relatively young age of our cohort (mean
31.6 ± 8.5 years) or perhaps due to a slight improvement of the
physical QoL of the French population in recent years. Nevertheless,
our observations appear consistent with data published more
recently by Briançon et al. (2011) from the SU.VI.MAX cohort.
Study participants with moderate to extremely severe stress at
baseline were selected for inclusion. Many of these participants also
presented with severe or extremely severe anxiety (52.3%), and
moderate to extremely severe depression (51.5%) both of which
frequently occur together. Study participants had reduced QoL at
baseline (primarily impaired mental subdomain scores, but also
impaired physical domain scores). Additionally, these participants
presented with suboptimal serum magnesium levels (range 0.66–
0.84 mmol/L). These baseline observations likely reflect known as-
sociations between chronic stress and dysregulation of the allostatic
system resulting in worse mood and anxiety and are consistent with
allostatic dysregulation in magnesium deficient subjects (McE-
wen, 2005, 2015). Indeed, the correlation between stress and
physical symptoms, such as fatigue, is well documented (Doerr
et al., 2015; Kocalevent et al., 2011), and thus the presence of stress
in combination with suboptimal magnesium levels may help explain
these baseline observations.
4.2 | Effect of vitamin B6 in addition to magnesium
on mental health and QoL
Consistent trends in favour of the magnesium and vitamin B6 com-
bination observed for the SF‐36 physical role functioning domain,
which were significant at Week 4, suggest that vitamin B6 augments
participants' perception of improvement in physical capacity to
perform activities, over and above the effect of magnesium alone.
This represents an interesting clinical insight, and further exploration
of this finding, which may help to elucidate the underlying mechanism
of action of the combination, is warranted. We observed greater
improvement in the SF‐36 general health domain with magnesium
alone relative to magnesium + vitamin B6 at Week 4. However, the
difference between groups was small and unlikely to be clinically
meaningful.
T A B L E 2 DASS‐42 anxiety and depression scores (adjusted means) by visit – change from baseline and treatment difference for two












Change from baseline to Week 4 Adjusted mean (SE) −5.69 (0.59)b −6.02 (0.58)b −5.86 (0.41)b 0.26 (0.66)
Change from baseline to Week 8 Adjusted mean (SE) −8.45 (0.59)b −9.03 (0.59)b −8.74 (0.41)b 0.54 (0.66)
DASS‐42 depression
Change from baseline to Week 4 Adjusted mean (SE) −5.69 (0.65)b −5.39 (0.69)b −5.54 (0.47)b −0.41 (0.75)
Change from baseline to Week 8 Adjusted mean (SE) −8.04 (0.65)b −8.12 (0.69)b −8.08 (0.47)b −0.05 (0.75)
Note: No significant differences (p < 0.05) in the change from baseline were identified between the magnesium + vitamin B6 group and magnesium
group.
Change from baseline was calculated using MMRM including sex and visit as categorical fixed effects, DASS‐42 at baseline as continuous fixed effect
and subject as random effect.
Treatment difference was calculated using MMRM including sex, visit, and treatment group as categorical fixed effects and DASS‐42 at baseline as
continuous fixed effect, DASS‐42 at baseline x treatment group, visit x treatment group as interaction terms and subject as random effect.
Abbreviations: DASS‐42, Depression Anxiety Stress Scales; ITT, intent‐to‐treat; MMRM, Model Mixed for Repeated Measures; SE, standard error.
aOverall group corresponds to the pooling of the magnesium + vitamin B6 group and magnesium group.
bp‐value testing for a significant decrease within each treatment group. A p‐value < 0.05 was considered significant.
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T A B L E 3 SF‐36 change from baseline (adjusted mean differences) by visit with comparison between both magnesium supplemented














Change from baseline to Week 4 Adjusted mean (SE) 1.8 (0.9)b 1.7 (1.0) 1.7 (0.7)b −0.3 (1.2)
Change from baseline to Week 8 Adjusted mean (SE) 4.2 (0.9)b 5.0 (1.0)b 4.6 (0.7)b −1.2 (1.2)
Physical role functioning
Change from baseline to Week 4 Adjusted mean (SE) 14.6 (2.5)b 4.6 (2.7) 9.6 (1.9)b 7.8 (3.4)c
Change from baseline to Week 8 Adjusted mean (SE) 22.4 (2.5)b 13.7 (2.7)b 18.1 (1.9)b 6.5 (3.5)
Bodily pain
Change from baseline to Week 4 Adjusted mean (SE) 6.2 (1.5)b 7.0 (1.4)b 6.6 (1.0)b 0.1 (1.9)
Change from baseline to Week 8 Adjusted mean (SE) 7.4 (1.5)b 10.3 (1.4)b 8.8 (1.0)b −1.9 (1.9)
General health
Change from baseline to Week 4 Adjusted mean (SE) 4.6 (1.0)b 8.1 (1.1)b 6.3 (0.7)b −2.7 (1.4)c
Change from baseline to Week 8 Adjusted mean (SE) 7.7 (1.0)b 9.3 (1.1)b 8.5 (0.7)b −0.8 (1.4)
Physical summary score
Change from baseline to Week 4 Adjusted mean (SE) 0.1 (0.5) 0.2 (0.5) 0.2 (0.3) 0.0 (0.6)
Change from baseline to Week 8 Adjusted mean (SE) 0.8 (0.5) 1.0 (0.5)b 0.9 (0.3)b −0.2 (0.6)
Mental domains
Vitality
Change from baseline to Week 4 Adjusted mean (SE) 13.6 (1.4)b 11.4 (1.3)b 12.5 (1.0)b 0.9 (1.8)
Change from baseline to Week 8 Adjusted mean (SE) 18.4 (1.4)b 17.1 (1.3)b 17.7 (0.9)b 0.0 (1.8)
Social functioning
Change from baseline to Week 4 Adjusted mean (SE) 12.8 (1.6)b 14.2 (1.8)b 13.5 (1.2)b −0.4 (2.3)
Change from baseline to Week 8 Adjusted mean (SE) 21.5 (1.6)b 21.1 (1.8)b 21.3 (1.2)b 1.5 (2.3)
Emotional role functioning
Change from baseline to Week 4 Adjusted mean (SE) 27.4 (3.0)b 22.3 (3.3)b 24.9 (2.2)b 4.4 (4.2)
Change from baseline to Week 8 Adjusted mean (SE) 35.3 (3.0)b 33.7 (3.3)b 34.5 (2.2)b 1.0 (4.2)
Emotional well being
Change from baseline to Week 4 Adjusted mean (SE) 14.0 (1.3)b 11.4 (1.3)b 12.7 (0.9)b 1.7 (1.7)
Change from baseline to Week 8 Adjusted mean (SE) 19.8 (1.3)b 17.3 (1.3)b 18.6 (0.9)b 1.5 (1.7)
Mental summary score
Change from baseline to Week 4 Adjusted mean (SE) 9.4 (0.8)b 8.3 (0.9)b 8.9 (0.6)b 0.7 (1.1)
Change from baseline to Week 8 Adjusted mean (SE) 13.0 (0.8)b 12.0 (0.9)b 12.5 (0.7)b 0.6 (1.1)
Note: Change from baseline was calculated using MMRM including sex and visit as categorical fixed effects, SF‐36 at baseline as continuous fixed effect
and subject as random effect.
Treatment difference was calculated using MMRM including sex, visit, and treatment group as categorical fixed effects and SF‐36 at baseline as
continuous fixed effect, SF‐36 at baseline x treatment group, visit x treatment group as interaction terms and subject as random effect.
Abbreviations: CI, confidence interval; ITT, intent‐to‐treat; MMRM, Model Mixed for Repeated Measures; SE, standard error; SF‐36, Short Form‐36
Health Survey.
aOverall group corresponds to the pooling of the magnesium + vitamin B6 group and magnesium group.
bp‐value testing for a significant decrease within each treatment group. A p‐value < 0.05 was considered significant.
cp‐value testing the effect of treatment in the change from baseline between magnesium + vitamin B6 and magnesium. A p‐value < 0.05 was considered
significant.
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A beneficial additive effect of magnesium and vitamin B6 treat-
ment has been previously demonstrated on anxiety (for a review see
Boyle et al., 2017), stress (Pouteau et al., 2018) and premenstrual
syndrome (Fathizadeh et al., 2010; De Souza et al., 2000). However,
we did not observe an additive effect; improvement in anxiety and
depression scores with magnesium + vitamin B6 was equivalent to
that seen with magnesium alone. One possible reason for the
discordance could be the variation in anxiety and depression re-
ported by our study participants at baseline. We have previously
observed a synergistic effect for magnesium and vitamin B6 in stress
reduction in a severely/extremely severely stressed population
(Pouteau et al., 2018). Secondly, the lack of observed differential
effect of addition of vitamin B6 in our study may be influenced by
magnesium status at baseline. Vitamin B6 has been postulated to
enhance magnesium absorption or cell penetration, but in the pre-
sent study, very few participants (6/264; 2.3%) had frank hypo-
magnesaemia (serum magnesium levels <0.7 mmol/L, by definition)
despite all having suboptimal magnesemia (<0.85 mmol/L). Further
comparison with data from the literature is difficult since magnesium
levels were not consistently reported in previous studies (Boyle
et al., 2017; De Souza et al., 2000; Fathizadeh et al., 2010).
4.3 | Limitations
Our analysis has some limitations. It is a post‐hoc analysis of a study
not being primarily designed for the analyses of subjective anxiety,
depression and QoL. The selected nature of our study sample, and
that data collected using both the SF‐36 and DASS‐42 question-
naires are self‐reported, requires that our findings be interpreted
with a degree of caution. Furthermore, the study did not include a
placebo group and it was not possible to collect the ethnicity of the
participants due to French ethical legislation. While we did request
that participants abstained from taking medications known to affect
magnesium levels and from consuming magnesium‐rich foods and
water, dietary intake remains a potential limitation. With these
limitations in mind, our findings should be considered exploratory
and require confirmation in an appropriately designed follow‐up
study.
5 | CONCLUSION
The analyses presented suggest that magnesium treatment has po-
tential benefit for the symptomatic treatment of stress‐associated
mood and anxiety, and may improve self‐reported QoL. There now
exists a growing body of evidence supporting the use of magnesium
to improve stress‐related mental health, and further investigation is
warranted to explore whether the addition of vitamin B6 may also
offer additional benefits in such populations.
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